Literature DB >> 22230565

Engineering cyclic peptide toxins.

Richard J Clark1, David J Craik.   

Abstract

Peptide-based toxins have attracted much attention in recent years for their exciting potential applications in drug design and development. This interest has arisen because toxins are highly potent and selectively target a range of physiologically important receptors. However, peptides suffer from a number of disadvantages, including poor in vivo stability and poor bioavailability. A number of naturally occurring cyclic peptides have been discovered in plants, animals, and bacteria that have exceptional stability and potentially ameliorate these disadvantages. The lessons learned from studies of the structures, stabilities, and biological activities of these cyclic peptides can be applied to the reengineering of toxins that are not naturally cyclic but are amenable to cyclization. In this chapter, we describe solid-phase chemical synthetic methods for the reengineering of peptide toxins to improve their suitability as therapeutic, diagnostic, or imaging agents. The focus is on small disulfide-rich peptides from the venoms of cone snails and scorpions, but the technology is potentially widely applicable to a number of other peptide-based toxins.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22230565     DOI: 10.1016/B978-0-12-396962-0.00003-3

Source DB:  PubMed          Journal:  Methods Enzymol        ISSN: 0076-6879            Impact factor:   1.600


  7 in total

1.  Backbone cyclization of analgesic conotoxin GeXIVA facilitates direct folding of the ribbon isomer.

Authors:  Xiaosa Wu; Yen-Hua Huang; Quentin Kaas; Peta J Harvey; Conan K Wang; Han-Shen Tae; David J Adams; David J Craik
Journal:  J Biol Chem       Date:  2017-08-28       Impact factor: 5.157

2.  Development of Novel Melanocortin Receptor Agonists Based on the Cyclic Peptide Framework of Sunflower Trypsin Inhibitor-1.

Authors:  Thomas Durek; Philipp M Cromm; Andrew M White; Christina I Schroeder; Quentin Kaas; Joachim Weidmann; Abdullah Ahmad Fuaad; Olivier Cheneval; Peta J Harvey; Norelle L Daly; Yang Zhou; Anita Dellsén; Torben Österlund; Niklas Larsson; Laurent Knerr; Udo Bauer; Horst Kessler; Minying Cai; Victor J Hruby; Alleyn T Plowright; David J Craik
Journal:  J Med Chem       Date:  2018-04-11       Impact factor: 7.446

Review 3.  Targeted drug delivery for cancer therapy: the other side of antibodies.

Authors:  Michael A Firer; Gary Gellerman
Journal:  J Hematol Oncol       Date:  2012-11-09       Impact factor: 17.388

4.  Less is More: Design of a Highly Stable Disulfide-Deleted Mutant of Analgesic Cyclic α-Conotoxin Vc1.1.

Authors:  Rilei Yu; Victoria A L Seymour; Géza Berecki; Xinying Jia; Muharrem Akcan; David J Adams; Quentin Kaas; David J Craik
Journal:  Sci Rep       Date:  2015-08-20       Impact factor: 4.379

Review 5.  G-Protein Coupled Receptors Targeted by Analgesic Venom Peptides.

Authors:  James T Daniel; Richard J Clark
Journal:  Toxins (Basel)       Date:  2017-11-16       Impact factor: 4.546

6.  Accelerating chemoselective peptide bond formation using bis(2-selenylethyl)amido peptide selenoester surrogates.

Authors:  Laurent Raibaut; Marine Cargoët; Nathalie Ollivier; Yun Min Chang; Hervé Drobecq; Emmanuelle Boll; Rémi Desmet; Jean-Christophe M Monbaliu; Oleg Melnyk
Journal:  Chem Sci       Date:  2016-01-11       Impact factor: 9.825

Review 7.  Neuronal Nicotinic Acetylcholine Receptor Modulators from Cone Snails.

Authors:  Nikita Abraham; Richard J Lewis
Journal:  Mar Drugs       Date:  2018-06-13       Impact factor: 5.118

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.